8月27日，诺和诺德盘中下跌3.03%，报45.76美元/股，成交额1.33亿美元。
消息面上，中国国家药品监督管理局已受理诺和诺德口服版减肥药Wegovy（司美格鲁肽片剂）用于长期体重管理的上市申请。尽管该进展标志着公司在中国减重市场布局迈出关键一步，但当日医疗保健板块整体走弱，Health Care Select Sector SPDR ETF盘前下跌0.7%，iShares生物科技ETF下跌0.5%。此外，竞争对手礼来口服减重药Foundayo已率先在欧洲获批，且替尔泊肽上半年全球销售额达277亿美元，GLP-1赛道竞争格局持续对诺和诺德估值形成压制。制药行业个股普遍承压，强生跌2.1%，默沙东跌2.0%，辉瑞跌1.66%，礼来跌0.94%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.